ATE413388T1 - Muskarin antagonisten - Google Patents

Muskarin antagonisten

Info

Publication number
ATE413388T1
ATE413388T1 AT03726436T AT03726436T ATE413388T1 AT E413388 T1 ATE413388 T1 AT E413388T1 AT 03726436 T AT03726436 T AT 03726436T AT 03726436 T AT03726436 T AT 03726436T AT E413388 T1 ATE413388 T1 AT E413388T1
Authority
AT
Austria
Prior art keywords
sup
formula
compound
muscarine antagonists
methods
Prior art date
Application number
AT03726436T
Other languages
German (de)
English (en)
Inventor
Craig Boyle
William Greenlee
Samuel Chackalamannil
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE413388T1 publication Critical patent/ATE413388T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT03726436T 2002-04-26 2003-04-24 Muskarin antagonisten ATE413388T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37609302P 2002-04-26 2002-04-26

Publications (1)

Publication Number Publication Date
ATE413388T1 true ATE413388T1 (de) 2008-11-15

Family

ID=29270760

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03726436T ATE413388T1 (de) 2002-04-26 2003-04-24 Muskarin antagonisten

Country Status (11)

Country Link
US (1) US6890936B2 (enExample)
EP (1) EP1499596B1 (enExample)
JP (2) JP4527408B2 (enExample)
CN (1) CN1649845A (enExample)
AT (1) ATE413388T1 (enExample)
AU (1) AU2003228674A1 (enExample)
CA (1) CA2484217A1 (enExample)
DE (1) DE60324544D1 (enExample)
ES (1) ES2315494T3 (enExample)
MX (1) MXPA04010552A (enExample)
WO (1) WO2003091220A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1622569B1 (en) 2003-04-24 2015-12-02 Incyte Corporation Aza spiro alkane derivatives as inhibitors of metallproteases
AU2005287037A1 (en) * 2004-09-20 2006-03-30 Targacept, Inc. Azaspiroalkene and azaspiroalkane compounds with nicotinic cholinergic receptor activity
EP2275096A3 (en) * 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
EP2066355A2 (en) * 2006-09-19 2009-06-10 Braincells, Inc. Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis
AU2007299726A1 (en) * 2006-09-22 2008-03-27 Braincells, Inc. Combination comprising an HMG-COA reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis
WO2008039863A2 (en) * 2006-09-27 2008-04-03 Braincells, Inc. Composition comprising a melanocortin receptor (mcr) modulating agent alone or in combination with a second neurogenic agent for treating nervous system disorders
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
TW200902007A (en) * 2007-05-25 2009-01-16 Astrazeneca Ab Spirocyclopropyl piperidine derivatives
US20100130477A1 (en) * 2008-11-25 2010-05-27 Astrazeneca Ab Spirocyclobutyl Piperidine Derivatives
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
EP2533645B1 (en) 2010-02-09 2016-07-27 The Johns Hopkins University Methods and compositions for improving cognitive function
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
MX2012010470A (es) 2010-03-10 2012-10-09 Probiodrug Ag Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5).
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
WO2011143457A2 (en) 2010-05-12 2011-11-17 Northwestern University Compositions and methods for treating or preventing atrial fibrillation
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
CA2904767C (en) 2013-03-15 2022-06-21 Agenebio, Inc. Methods and compositions for improving cognitive function
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
CA2964103C (en) * 2014-10-31 2022-08-30 Indivior Uk Limited Dopamine d3 receptor antagonist compounds
EA034167B8 (ru) 2015-05-22 2021-04-27 Эйджинбайо, Инк. Фармацевтические композиции леветирацетама пролонгированного высвобождения
EP3651762B1 (en) 2017-07-12 2024-07-03 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
JP7270989B2 (ja) 2017-10-20 2023-05-11 ヴァンダービルト ユニバーシティー ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
EP3732163A4 (en) * 2017-12-20 2021-07-14 Vanderbilt University MUSCARIN M4 ACETYLCHOLIN RECEPTOR ANTAGONISTS
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04225953A (ja) * 1990-05-07 1992-08-14 Shionogi & Co Ltd スピロ　ジベンゾスベラン誘導体
GB9309422D0 (en) * 1993-05-07 1993-06-23 Res Inst Medicine Chem Chemical compounds
AU2206699A (en) * 1997-12-23 1999-07-12 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
US7164024B2 (en) * 2001-04-20 2007-01-16 Banyu Pharmaceutical Co., Ltd. Benzimidazolone derivatives

Also Published As

Publication number Publication date
MXPA04010552A (es) 2005-01-25
JP2010059213A (ja) 2010-03-18
US6890936B2 (en) 2005-05-10
EP1499596B1 (en) 2008-11-05
US20040067972A1 (en) 2004-04-08
DE60324544D1 (de) 2008-12-18
JP4527408B2 (ja) 2010-08-18
HK1068136A1 (en) 2005-04-22
CN1649845A (zh) 2005-08-03
ES2315494T3 (es) 2009-04-01
CA2484217A1 (en) 2003-11-06
EP1499596A1 (en) 2005-01-26
JP2006507220A (ja) 2006-03-02
AU2003228674A1 (en) 2003-11-10
WO2003091220A1 (en) 2003-11-06

Similar Documents

Publication Publication Date Title
DE60324544D1 (de) Muskarin antagonisten
IL166271A0 (en) Pyrrolidinedione substituted piperidine phthalazone derivatives and pharmaceutical compositions containing the same
UA88012C2 (uk) Похідні хіназоліндіону як інгібітори parp
SE0101675D0 (sv) Novel composition
ATE433447T1 (de) Pyrimiidinverbindungen
ATE425149T1 (de) ANILINOPYRIMIDIN DERIVATE ALS ßJNK PATHWAY INHIBITORENß, ZUSAMMENSETZUNGEN UND DAMIT VERBUNDENE BEHANDLUNGSMETHODEN
BRPI0410630A (pt) antagonista de nk1
DE60142921D1 (de) Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren
IS6658A (is) Ný efnasambönd
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
DK0842934T3 (da) 5-HT1F agonister
ATE250590T1 (de) Neuartiger p2x 7 rezeptor-antagonisten zur verwendung in der behandlung von entzündlichen, immuninduzierten erkrankungen oder erkrankungen des herz-kreislauf-systems
UA93351C2 (uk) Похідні фталазіну як інгібітори parp
ATE374190T1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
ATE498600T1 (de) Inden derivate als pharmazeutika
DE60323942D1 (de) Lipase-hemmende zusammensetzung
ATE359283T1 (de) Substituierte pyrazinonverbindungen zur behandlung von entzündungen
SE0003476D0 (sv) Compounds
BR0212899A (pt) Compostos orgânicos
AP2001002188A0 (en) 5HT1 antagonists for antidepressant therapy.
ATE335739T1 (de) Cak inhibitoren und deren verwendungen
ID25478A (id) Agonis 5-ht1f
ATE394105T1 (de) Substituierte 4,5-dihydro-1,2,4-triazin-3-one, 1, 2,4-triazin-3-one sowie deren verwendung als fungizide und insektizide
GB0223223D0 (en) Organic compounds
NO20042138L (no) Forbindelser og fremgangsmate for behandling av hyperaktiv blaere

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties